Loading clinical trials...
Loading clinical trials...
A Phase 2, Open Label, Uncontrolled, Multicenter Study to Evaluate Safety and Immunogenicity of a Surface Antigen, Inactivated, Adjuvanted With MF59C.1 Influenza Vaccine (Fluad®), Formulation 2012/2013, When Administered to Elderly Subjects
Conditions
Interventions
Adjuvanted Trivalent Influenza Virus Vaccine (aTIV)
Locations
1
Belgium
University Hospital Ghent Center for Vaccinology
De Pintelaan, Be-9000 Ghent, Belgium
Start Date
July 1, 2012
Primary Completion Date
August 1, 2012
Completion Date
August 1, 2012
Last Updated
April 21, 2014
NCT04682444
NCT04431050
NCT02387294
NCT03448705
NCT03572491
NCT01879540
Lead Sponsor
Novartis Vaccines
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions